References
- Cuneo A, Ferrant A, Michaux J L, Demuynck H, Boogaerts M, Louwagie A, et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 1996; 81: 423–427
- Paietta E, Racevskis J, Bennett J M, Neuberg D, Cassileth P A, Rowe J M, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 1998; 12: 1881–1815
- Keung Y K, Beaty M, Powell B L, Molnar I, Buss D, Pettenati M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res 2004; 28: 579–586
- Onozawa M, Fukuhara T, Takahata M, Yamamoto Y, Miyake T, Maekawa I. A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL. Ann Hematol 2003; 82: 593–595
- Drummond M W, Lush C J, Vickers M A, Reid F M, Kaeda J, Holyoake T L. Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia 2003; 17: 463–465
- Ito K, Tominaga K, Suzuki T, Jinnai I, Bessho M. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. Int J Hematol 2005; 81: 242–245
- Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
- Ottmann O G, Druker B J, Sawyers C L, Goldman J M, Reiffers J, Silver R T, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971
- Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004; 104: 3507–3512
- Viniou N A, Vassilakopoulos T P, Giakoumi X, Mantzouranis M, Pangalis G A. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia. Eur J Haematol 2004; 72: 58–60
- Jentsch-Ullrich K, Pelz A F, Braun H, Koenigsmann M, Mohren M, Wieacker P, et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica 2004; 89, ECR 15 Available http//www.haematologica.org